Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET scans could sharpen stomach cancer detection

NCT ID NCT07528131

Diagnosis Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at whether a special PET scan using 18F-FDG can help doctors more accurately diagnose, stage, and track stomach cancer. Researchers studied 50 patients with confirmed gastric cancer, comparing scan results to other tests. The goal was to see if this imaging method could become a standard tool for managing the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG (a radioactive tracer used in PET scans)
What this could lead to
If successful, this could make gastric cancer diagnosis and monitoring more accurate and standardized using PET/CT imaging.
What could go wrong
This is a small, completed study with only 50 participants, so results may not apply broadly. The imaging technique is already in use, so major breakthroughs are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Sep 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The Current Retrospective and Prospective study was conducted among 50 histologically confirmed Gastric Cancer patients ,mean age of the studied cases was 57.58 ± 10.26 years and ranged between (35-77) years. Moreover, the study included 29 males (58%) and 21 females (42%).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed as Gastric Cancer on surgically resected specimens. 2. Patients with gastric and extragastric metastasis. 3. Patients with gastric cancer either operated or not Exclusion Criteria: 1. Patients with second malignancy (Double primary). 2. Patient without proven pathology of Cancer Stomach. 3. Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging). 4. Uncontrolled diabetic patient with blood glucose level more than 200mg\\dl. 5. Pregnant women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer

Contacts and locations

Locations

  • Sara Saber Ahmed

    Sohag, 82524, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.